Direct antivirals (grazoprevir and elbasvir) vs placebo
End‐of‐treatment response · patients on HD with HCV infection
Direct antivirals (grazoprevir and elbasvir) may leads to higher end‐of‐treatment response compared with placebo (low certainty).
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 174.99 [11.03, 2775.78]1 study · 173 participantsLow